Barclays
INO icon

Barclays’s Inovio Pharmaceuticals INO Stock Holding History

Barclays’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,167
Closed -$580K – 5037
2020
Q3 		$580K Buy
4,167
+3,334
+400% +$695K ﹤0.01% 3120
2020
Q2 		$270K Buy
+833
New +$134K ﹤0.01% 3835

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's INO Position: Q2 2026 in Review

Barclays increased its Inovio Pharmaceuticals (INO) stake by 589% in Q2 2026, buying an estimated $3.54K and bringing the position to 3,487 shares worth $3.84K. The position accounts for ﹤0.01% of the portfolio, ranked #4800.

Barclays first reported a position in INO in Q4 2013 and has held it in 48 quarters since. The position peaked at $7.02M in Q2 2020. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Barclays held 3,487 shares of Inovio Pharmaceuticals worth $3.84K as of Q2 2026.
  • Barclays bought 2,981 Inovio Pharmaceuticals shares in Q2 2026, an estimated $3.54K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4800 holding.
  • Barclays first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 48 quarters since.
  • Barclays's Inovio Pharmaceuticals position peaked at $7.02M in Q2 2020.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.